NPC1 and metabolic dysfunction-associated steatohepatitis: Given the mechanistic overlap between the pathologies of NPC1 disease and of the metabolic diseases atherosclerosis and NASH, the aim of the current study was to determine whether increasing anti-oxLDL IgM autoantibodies reduces NPC1 disease symptoms.